Skip to content

US · RADX · BIOTECHNOLOGY

Radiopharm Theranostics Limited (RADX) intrinsic value and stock valuation

$0.63as of 2026-11-21 · Mkt cap 3.61M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Radiopharm Theranostics Limited DCF and intrinsic value

InvestorsCraft values RADX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RADX’s statements →

Radiopharm Theranostics Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Carlton, VIC 3053 radiopharmtheranostics.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$3.63M
20222025
Net income
-$-38.34M
20222025
Free cash flow
-$-36.65M
20222025
Total equity
$42.9M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$3.63M$300K$290K$10K
Operating income-$-38.17M-$-36.62M-$-34.51M-$-19.92M
Net income-$-38.34M-$-47.95M-$-34.61M-$-30.34M
EPSd-$-5.52M-$-37.17M-$-33.93M-$-29.75M
Operating cash flow-$-36.65M-$-22.98M-$-23.2M-$-9.92M
Capital expenditure$0.00$0.00-$-1.53M-$-28.34M
Free cash flow-$-36.65M-$-22.98M-$-24.73M-$-38.25M
Total assets$86.5M$72M$75M$83.4M
Total debt$0.00$0.00$0.00$0.00
Net debt-$-29.12M-$-18.58M-$-11.7M-$-26.98M
Total equity$42.9M$27.4M$45.6M$63M
Cash and short-term investments$29.1M$18.6M$11.7M$27M
Income statement
2025202420232022
Revenue$3.63M$300K$290K$10K
Cost of revenue$3.59M$0.00$0.00$0.00
Gross profit$40K$300K$290K$10K
Research and development expenses$27.5M$17.6M$13.8M$4.12M
Selling, general and administrative expenses$16.5M$15.2M$13M$10.9M
Other expenses-$-5.83M$4.14M$7.98M$4.95M
Operating expenses$38.2M$36.9M$34.8M$19.9M
Cost and expenses$41.8M$36.9M$34.8M$19.9M
Interest income$890K$50K$150K$0.00
Interest expense$70K$640K$90K$9.35M
Depreciation and amortization$10K$3.13M$3.3M$2.98M
Ebitda-$-38.17M-$-44.08M-$-31.19M-$-17.96M
Operating income-$-38.17M-$-36.62M-$-34.51M-$-19.92M
Total other income/expenses, net-$-70K-$-11.23M-$-70K-$-10.38M
Income before tax-$-38.24M-$-47.85M-$-34.57M-$-30.29M
Income tax expense$100K$100K$40K$40K
Net income-$-38.34M-$-47.95M-$-34.61M-$-30.34M
Weighted average shares outstanding$6.94M$1.29M$1.02M$1.02M
Weighted average diluted shares outstanding$6.94M$1.29M$1.02M$1.02M
Balance sheet
2025202420232022
Cash and short-term investments$29.1M$18.6M$11.7M$27M
Net receivables$10.4M$990K$4.47M$60K
Inventory$0.00$0.00$0.00$0.00
Total current assets$39.9M$22.9M$16.3M$27.3M
Property, plant and equipment, net$50K$60K$70K$0.00
Goodwill and intangible assets$46.6M$49.1M$58.5M$56.1M
Long-term investments$0.00$40K$0.00$0.00
Total non-current assets$46.6M$49.2M$58.7M$56.1M
Total assets$86.5M$72M$75M$83.4M
Accounts payable$6.35M$6.43M$2.96M$1.19M
Short-term debt$0.00$0.00$0.00$0.00
Deferred revenue$1.72M$0.00$0.00$0.00
Total current liabilities$14.9M$17.6M$13.2M$7.88M
Long-term debt$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$28.7M$27.1M$16.1M$12.5M
Capital lease obligations$0.00$0.00$0.00$0.00
Total liabilities$43.6M$44.7M$29.4M$20.4M
Common stock$176.6M$100.7M$97.2M$86.8M
Retained earnings-$-145.73M-$-111.34M-$-65.35M-$-30.82M
Accumulated other comprehensive income (loss)$13.1M$37.9M$10.4M$7.03M
Total equity$42.9M$27.4M$45.6M$63M
Total investments$0.00$40K$0.00$0.00
Total debt$0.00$0.00$0.00$0.00
Net debt-$-29.12M-$-18.58M-$-11.7M-$-26.98M
Cash flow statement
2025202420232022
Net income$0.00-$-47.95M-$-34.61M-$-30.34M
Depreciation and amortization$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00
Change in working capital$0.00$0.00$0.00$0.00
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-36.65M-$-22.98M-$-23.2M-$-9.92M
Investments in property, plant and equipment$0.00$0.00-$-50K-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities$1.77M-$-320K-$-1.53M-$-28.37M
Common stock issued$54M$29.7M$10.1M$70M
Common stock repurchased$0.00-$-1.53M-$-850K-$-4.83M
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$45.4M$30.2M$9.22M$65.1M
Net change in cash$10.5M$6.88M-$-15.28M$27M
Cash at end of period$29.1M$18.6M$11.7M$27M
Operating cash flow-$-36.65M-$-22.98M-$-23.2M-$-9.92M
Capital expenditure$0.00$0.00-$-1.53M-$-28.34M
Free cash flow-$-36.65M-$-22.98M-$-24.73M-$-38.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Radiopharm Theranostics Limited

        Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

        CEO
        Riccardo Canevari
        Employees
        14
        Beta
        0.80

        Explore

        Frequently asked questions

        What is the intrinsic value of Radiopharm Theranostics Limited (RADX)?

        InvestorsCraft does not currently publish an intrinsic value for RADX. How the IC value is calculated.

        Is RADX undervalued?

        InvestorsCraft does not publish an undervaluation signal for RADX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.